Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study is an evaluation of the safety of 625 mg formulation when administered to
HIV-infected pregnant women from their second trimester through six weeks postpartum. The
study will also evaluate the pharmacokinetics of VIRACEPT
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Lamivudine, zidovudine drug combination Nelfinavir